tetano
Editor, Senior Moderator
Oncotarget. 2017 Jun 17. doi: 10.18632/oncotarget.18533. [Epub ahead of print]
[h=1]A multiplex liquid-chip assay based on Luminex xMAP technology for simultaneous detection of six common respiratory viruses.[/h] Yan Y[SUP]1[/SUP], Luo JY[SUP]1[/SUP], Chen Y[SUP]2[/SUP], Wang HH[SUP]1[/SUP], Zhu GY[SUP]1[/SUP], He PY[SUP]1[/SUP], Guo JL[SUP]1[/SUP], Lei YL[SUP]3[/SUP], Chen ZW[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] We utilized one-step multiplex reverse transcription-PCR (RT-PCR) and Luminex xMAP technology to develop a respiratory multiplex liquid-chip assay (rMLA) for simultaneous detection of 6 common respiratory viruses, including influenza virus type A (FluA) and type B (FluB), para-influenza virus type 3 (PIV-3), respiratory syncytial virus (RSV), human metapneumovirus (MPV) and a threatening virus to China, Middle East Respiratory Syndrome coronavirus (MERS-CoV). Performance of rMLA was evaluated by comparing with real-time RT-PCR. Detection data from clinical specimens showed that the rMLA had diagnostic sensitivities of 97.10% for FluA, 94.59% for FluB, 98.68% for PIV-3, 94.87% for RSV and 95.92% for MPV (No Data for MERS-CoV due to the lack of positive specimens). Data of analytical sensitivities showed that the detection limits of the rMLA assay were 5-25 viral RNA copies per μl for FluA, FluB, PIV-3 and MERS-CoV, approximate to the real-time RT-PCR assay; while the values were 8 and 22copies/μl for MPV and RSV, lower than the real-time RT-PCR(78 and 114 copies/μl respectively). The results indicated that the rMLA is a sensitive, specific detection tool and comparable to real-time RT-PCR, especially suitable for high-throughput detection of respiratory specimens.
[h=4]KEYWORDS:[/h] Luminex; multiplex detection; real-time RT-PCR; respiratory virus; xMAP
PMID: 28636980 DOI: 10.18632/oncotarget.18533
Free full text
[h=1]A multiplex liquid-chip assay based on Luminex xMAP technology for simultaneous detection of six common respiratory viruses.[/h] Yan Y[SUP]1[/SUP], Luo JY[SUP]1[/SUP], Chen Y[SUP]2[/SUP], Wang HH[SUP]1[/SUP], Zhu GY[SUP]1[/SUP], He PY[SUP]1[/SUP], Guo JL[SUP]1[/SUP], Lei YL[SUP]3[/SUP], Chen ZW[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] We utilized one-step multiplex reverse transcription-PCR (RT-PCR) and Luminex xMAP technology to develop a respiratory multiplex liquid-chip assay (rMLA) for simultaneous detection of 6 common respiratory viruses, including influenza virus type A (FluA) and type B (FluB), para-influenza virus type 3 (PIV-3), respiratory syncytial virus (RSV), human metapneumovirus (MPV) and a threatening virus to China, Middle East Respiratory Syndrome coronavirus (MERS-CoV). Performance of rMLA was evaluated by comparing with real-time RT-PCR. Detection data from clinical specimens showed that the rMLA had diagnostic sensitivities of 97.10% for FluA, 94.59% for FluB, 98.68% for PIV-3, 94.87% for RSV and 95.92% for MPV (No Data for MERS-CoV due to the lack of positive specimens). Data of analytical sensitivities showed that the detection limits of the rMLA assay were 5-25 viral RNA copies per μl for FluA, FluB, PIV-3 and MERS-CoV, approximate to the real-time RT-PCR assay; while the values were 8 and 22copies/μl for MPV and RSV, lower than the real-time RT-PCR(78 and 114 copies/μl respectively). The results indicated that the rMLA is a sensitive, specific detection tool and comparable to real-time RT-PCR, especially suitable for high-throughput detection of respiratory specimens.
[h=4]KEYWORDS:[/h] Luminex; multiplex detection; real-time RT-PCR; respiratory virus; xMAP
PMID: 28636980 DOI: 10.18632/oncotarget.18533
Free full text